Sign in to view content

Episode 15: Serum VEGF Levels in the IVAN Trial with Dr. Usha Chakravarthy

Keyvan Koushan, MD, FRCSC

Audio
Published 2018

Related

96-Week Visual and Expanded Anatomical Outcomes of Brolucizumab Versus Aflibercept in Patients With nAMD: Results From HAWK and HARRIER
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2019
One Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Mark R. Barakat, MD
Updates from the Field
2020
Association Between Provider Anti-VEGF Injection Rates and Visual Outcome In Eyes With Neovascular Age-Related Macular Degeneration
Michael M. Lai, MD, PhD
Annual Meeting Talks
2024

Category: Pharmacology

See more